Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Citigroup Private Bank Appoints Chad Reddy as West Market Executive in North America 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Nvidia Nears $30 Billion Investment in OpenAI, Replacing Previous $100 Billion AI Partnership 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present at the Bank of America Merrill Lynch 2018 Health Care Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on May 17, 2018, at 10:40 a.m. P.T./ 1:40 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic, BMS-986249, a CTLA-4-targeting Probody therapeutic, CX-188, a PD-1-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Christopher Keenan
VP, Investor Relations and Corporate Communications
[email protected]
650-383-0823
